Topical agents

PreclinicalSmall molecule

Amgen

Topical agents is one of 37 small molecule programs targeting Tinea Pedis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tinea PedisActive, not recruiting

Kidney TransplantActive, not recruiting

Tinea PedisPreclinical

Active, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

Competition

Competitive Landscape

121 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Ultomiris

AstraZeneca

Phase 3

1 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 3

Felzartamab

Biogen

Phase 3

1 4

Biological/vaccine

Vertex Pharmaceuticals

Phase 3

1 5

Envarsus XR

UUniversity of Wisconsin, Madison

Phase 3

2 6

Cytogam

JJohns Hopkins University

Phase 3

2 7

Zemplar

AbbVie

Preclinical

2 8

Cysteine Hydrochloride

Novartis

Preclinical

1 9

Sensipar

Amgen

Preclinical

1 10

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

N/ANot yet recruiting

Kidney Transplant

NCT06929637

Clinical

Trials by Indication[1]

Psoriasis3 trials

Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT01313221·310 enrolled

A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

Completed· Amgen logo

Amgen·Phase 3·NCT03930186·152 enrolled

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT01194219·844 enrolled

Kidney Transplant1 trial

Amino Acid Infusion in Kidney Transplant Recipients

Not yet recruiting·UUniversity Hospital, Martin·N/A·NCT06929637·100 enrolled

Tinea Pedis1 trial

Safety and Efficacy of a Novel Topical Therapy for Tinea Pedis (Athlete's Foot)

Unknown status·HHillel Yaffe Medical Center·N/A·NCT00848666·100 enrolled

Hemodynamic1 trial

Impact of Fluid Management Within a Goal-directed Hemodynamic Protocol on Acid-base Balance in Elective Trauma Surgery

Completed·—·Phase 4·NCT01117519·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Topical agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Topical agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Topical agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Amgen

Topical agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Psoriasis3 trials

Kidney Transplant1 trial

Tinea Pedis1 trial

Hemodynamic1 trial

References

Drug Info

Quick Facts

Related News